Moreover, compared with other GLP-1 RAs, subcutaneous semaglutide (1 mg) and oral semaglutide (14 mg) administration yielded an improved reduction in body weight (WMD: 3.72 kg, 95% CI: 4.16 to 3.28, and WMD: 2.03 kg, 95% CI: 2.91 to 1.15, respectively)
The escalation schedule provides a framework, not a mandate
You can read the full article atYou can read the full article at Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial Due to increased obesity and inactivity rates, type 2 diabetes (T2D) is a complex, multifaceted disease with a rising prevalence rate
The best program is one that is medically supervised and personalized
A single missed dose rarely causes permanent weight gain
Mohan, A